NavigAID for autoimmune disease

Autoimmune diseases are highly diverse, yet can cause similar symptoms in different patients, making accurate diagnoses and development of effective treatments difficult. Therefore, solving the problem of patient heterogeneity is pivotal for the clinical development of effective and potentially curative therapies.

One solution is to stratify patients based on the specific characteristics of their individual autoimmune disease, to enable accurate diagnoses and response prediction to therapy during drug development, and so increasing the chances of treatment success.

Using its proprietary SeroTag® biomarker identification platform, Protagen has developed a pipeline of stratification arrays based on biomarker panels (NavigAID) to screen patient serum for an array of autoimmune diseases, such as Systemic Sclerosis (NavigAID SSc) and Systemic Lupus Erythematosus (NavigAID SLE). Additional NavigAID biomarker panels are under development for other autoimmune diseases, such as Rheumatoid arthritis and Sjögren’s syndrome.

By separating patients into disease subgroups NavigAID can:

  • Assess the specific immunological processes underpinning the disease
  • Improve response prediction to treatment and increase the chances of treatment success

NavigAID SSc

NavigAID SSc is a disease stratification array for Systemic Sclerosis (SSc) developed to separate and define disease-specific subgroups to improve disease activity assessment and response prediction for effective drug development.


NavigAID SLE is a stratification tool, which separates and defines subgroups of Systemic Lupus Erythematosus (SLE) patients to overcome heterogeneity and enable novel approaches for successful drug development.


NavigAID RA is being developed to stratify patients suffering from Rheumatoid arthritis (RA) into disease subgroups to facilitate the development of targeted treatments and increase the chances of favourable treatment responses.

NavigAID SjS

Protagen is developing a NavigAID platform for Sjögren’s syndrome to stratify patients and aid response prediction for the development of more effective, targeted therapeutics.